Who is sponsoring NCT07347444?

NCT07347444 is sponsored by Fudan University.

What condition does NCT07347444 study?

NCT07347444 studies Acral Melanoma, Mucosal Melanoma.

What drugs are being tested in NCT07347444?

Interventions: Iparomlimab and Tuvoraleimab injection+Bev+nab-PC.

What is the status of NCT07347444?

NCT07347444 is currently NOT_YET_RECRUITING.

Last reviewed 2026-01-15 · How we verify

A Prospective, Single-arm, Multicenter, Phase II Clinical Study of Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma

NCT07347444 Phase 2 NOT_YET_RECRUITING

This is a prospective, single-arm, multicenter, phase II clinical trial designed to evaluate the efficacy and safety of iparomlimab and tuvoraleimab, in combination with bevacizumab, albumin-bound paclitaxel, and carboplatin as first- or second-line treatment in patients with acral and mucosal melanoma.

Details

Lead sponsor	Fudan University
Phase	Phase 2
Status	NOT_YET_RECRUITING
Enrolment	48
Start date	2026-02
Completion	2028-12

Conditions

Acral Melanoma
Mucosal Melanoma

Interventions

Iparomlimab and Tuvoraleimab injection+Bev+nab-PC

Primary outcomes

Objective response rate (ORR) — up to 2 years
Defined as the percentage of participants in the analysis population who experienced a Complete Response or a Partial Response and was assessed using RECIST 1.1 based on investigator evaluation.

Countries

China